- ANCA-associated vasculitis
- Secondary glomerular disease
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
On this page
MPA is treated with medications that suppress the immune system, which can lower an individual's resistance to infections. There are a variety of immune suppressing medications that are used in MPA; however, resources state that a steroid (usually prednisone) and a medication toxic to cells (usually starting with cyclophosphamide) are typically prescribed first. The goal of treatment is to stop all of the organ damage that occurs as a result of MPA. The duration of treatment with immune suppressing medication varies between individuals, but is typically given for at least one to two years.
Last updated: 2/4/2009
- Microscopic polyangiitis. The Johns Hopkins Vasculitis Center Web site. 2014; http://www.hopkinsvasculitis.org/types-vasculitis/microscopic-polyangiitis/. Accessed 8/13/2014.
- Microscopic Polyangiitis. Cleveland Clinic Web site. November 10, 2010; http://my.clevelandclinic.org/disorders/microscopic_polyangiitis/hic_microscopic_polyangitis.aspx. Accessed 8/13/2014.
- Finding Treatment Information - A video developed by GARD Information Specialists that explains how you can find information about treatment for a rare disease.
- ClinicalTrials.gov lists trials that are studying or have studied Microscopic polyangiitis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.
The FDA has approved this product to be used in this manner.
|For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of pateints with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).|
|More Information about this product||
Drug Information Portal
Medline Plus Health Information